FDA speeds up review of Droxidopa
The drug is marketed in Japan to treat low blood pressure.
The Food and Drug Administration has given fast-track designation to Droxidopa, which is marketed in Japan to treat low blood pressure. Such a designation is reserved for drugs that treat serious conditions for which there is an unmet need. The maker of the drug, Chelsea Therapeutics International, says it plans to seek marketing approval for Droxidopa after completing clinical trials this year.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, clickhere.
Recent Videos
Related Content
